Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
Drug Therapy01:28

Drug Therapy

96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Evidence and opportunities for preeclampsia and cardiovascular disease prevention in malaria endemic settings.

Communications medicine·2026
Same author

Maternal Readiness for Newborn Self-Care in the Early Postpartum Period: Associations with Maternal Psychophysical State and Declared Breastfeeding Readiness.

Journal of clinical medicine·2026
Same author

Balancing policy ambition and systems reality in expanding access to NCD medicines: lessons from Ghana and Georgia.

Health policy and planning·2026
Same author

Obesity Definitions and Hospital Stay in Older Adults with Heart Failure: A Post Hoc Analysis of a Prospective Cohort.

Cardiac failure review·2026
Same authorSame journal

A Thematic Analysis of Key Informant Interviews on the Implementation Experience of the HEARTS Hypertension Program in Nigeria.

Global heart·2026
Same author

A measurement comparability study to support instrument harmonization in the Canadian longitudinal study on aging.

American journal of epidemiology·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026
Same journal

Understanding Behavioural Determinants of Cardiovascular Disease and Stroke Prevention Among Culturally and Linguistically Diverse Communities: A Qualitative Descriptive Study.

Global heart·2026
Same journal

Co-Developing Strategies for Patient Engagement in Decentralized Rheumatic Heart Disease Care: Lessons from Northern Uganda.

Global heart·2026
Same journal

<i>Streptococcus Pyogenes</i> and Acute Rheumatic Fever: How Strong are the Links in the Chain?

Global heart·2026
Same journal

Joint Associations of Cumulative C-Reactive Protein-Triglyceride-Glucose Index and Depression with Cardiovascular Outcomes in Middle-Aged and Older Adults: A National Prospective Cohort Study.

Global heart·2026
関連記事をすべて見る

関連する実験動画

Updated: Sep 9, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.8K

WHFの単一錠剤併用療法に関するロードマップ

Enrico G Ferro1,2, Gautam Satheesh3,4,5, José Castellano6

  • 1Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.

Global heart
|September 2, 2025
PubMed
まとめ
この要約は機械生成です。

シングル・ピル・コンビネーション (SPC) は,心血管疾患 (CVD) の治療順守を改善し,リスクを軽減します. このロードマップは,特にリソースが少ない環境で,より広範なSPCの実施のための障壁に対処し,解決策を提供しています.

キーワード:
心血管疾患ポリピル予防する単一の錠剤の組み合わせ

さらに関連する動画

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

関連する実験動画

Last Updated: Sep 9, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

科学分野:

  • 心臓病科
  • 公衆衛生
  • 医療システム研究

背景:

  • 心血管疾患 (CVD) は,世界の主要な死因です.
  • 治療の順守が悪いことは,CVDの予防と管理の重要な障害です.
  • シングル・ピル・コンビネーション (SPC) は 薬剤の投与手順を簡素化し 患者さんの服従を向上させる戦略です

研究 の 目的:

  • 心血管疾患 (CVD) の管理のためのシングルピル・コンビネーション (SPC) に関する現在の臨床的証拠を統合する.
  • 世界的にSPCの普及とアクセシビリティを妨げている主要な障壁を特定する.
  • 国家保健戦略へのSPCの統合を改善するために,実行可能な,文脈特有の解決策を提案する.

主な方法:

  • SPCに関する最新の臨床的証拠の包括的なレビュー.
  • 実施課題を特定するために,世界的な専門家の投入と健康システムの分析.
  • スケールアップとアクセシビリティのための実用的な戦略を備えたロードマップの作成

主要な成果:

  • SPCは治療の順守を効果的に改善し,心血管疾患のリスクを軽減します.
  • 主な障壁には,製造の制限,コスト,規制上の障害,および一貫していない臨床ガイドラインが含まれます.
  • このロードマップは,低所得国や中所得国を優先して,さまざまな医療環境に合わせた解決策を提供します.

結論:

  • 特定された障壁に対処することは,CVDの予防におけるSPCの利点を最大化するために極めて重要です.
  • 提案されたソリューションの実施は,SPCへのアクセスと有効な利用を向上させることができます.
  • このロードマップは,エビデンスに基づいた患者中心の戦略を通じてCVDケアを改善することを目指す利害関係者にとって重要なリソースとして機能します.